Amgen will acquire Horizon Therapeutics, a biopharmaceutical company that focuses on treatments for rare autoimmune diseases, in a deal valued at $26.4 billion.
Each Horizon shareholder will receive $116.50 per share for each share they own. Amgen said Monday that the deal has an enterprise value of about $28.3 billion.
Amgen confirmed discussions were taking place in early this month and said at the time that any offer it made for Horizon likely would be in cash, but also that there was no guarantee an offer would be made.Horizon Therapeutics, based in Dublin, develops potential treatments for rare, autoimmune and severe inflammatory diseases. Its best-seller, Tepezza, is only approved in the United States and treats eye bulging and double vision from thyroid eye disease.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Amgen to buy Horizon Therapeutics in $26.4B dealAmgen is spending more than $26 billion to dive deeper into rare disease treatments with the acquisition of drugmaker Horizon Therapeutics. The biotech drug developer said Monday that it will pay $116.50 in cash for each share of Horizon, which makes a treatment for thyroid eye disease that generated more than $1 billion in its first full year on the market.
続きを読む »
Amgen set to buy biotech firm Horizon at $26 bln valuation - Bloomberg NewsAmgen Inc is set to buy biotech firm Horizon Therapeutics Plc at a valuation of about $26 billion in what would be its largest acquisition, Bloomberg News reported on Monday.
続きを読む »
Amgen reportedly in talks to buy Horizon TherapeuticsThe U.S. biotechnology company AMGN was the last of three suitors standing in an auction for Horizon, according to sources cited by The Wall Street Journal.
続きを読む »
WSJ News Exclusive | Amgen in Advanced Talks to Buy Horizon TherapeuticsAmgen is in advanced talks to buy drugmaker Horizon Therapeutics, people familiar with the matter say, in a deal likely to be valued at well over $20 billion
続きを読む »
Amgen confirms to acquire Horizon Therapeutics in cash deal valued at about $27.8 billionAmgen Inc. undefined said Monday it has agreed to acquire Horizon Therapeutics Plc undefined in an all-cash deal valued at $27.8 billion, confirming earlier...
続きを読む »
Amgen Agrees to Deal to Buy Horizon TherapeuticsThe U.S. biotech company agreed to buy drugmaker Horizon Therapeutics in a deal valued at $27.8 billion, marking the largest healthcare merger of the year.
続きを読む »